

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

**IN RE: GENERIC PHARMACEUTICALS
PRICING ANTITRUST LITIGATION**

**MDL 2724
16-MD-2724**

**IN RE: CLOBETASOL CASES
IN RE: CLOMIPRAMINE CASES**

**HON. CYNTHIA M.
RUFÉ**

THIS DOCUMENT RELATES TO:

***ALL END-PAYER PLAINTIFF CLOBETASOL
CASES***

16-CB-27242

***ALL END-PAYER PLAINTIFF CLOMIPRAMINE
CASES***

16-CM-27242

ORDER

AND NOW, this 28th day of July 2021, upon consideration of the attached Stipulation regarding answer deadlines, it is hereby **ORDERED** that the Stipulation is **APPROVED**.

It is so **ORDERED**.

BY THE COURT:

/s/ Cynthia M. Rufe

CYNTHIA M. RUFÉ, J.

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

**IN RE: GENERIC PHARMACEUTICALS
PRICING ANTITRUST LITIGATION**

**MDL 2724
16-MD-2724
HON. CYNTHIA M. RUFE**

THIS DOCUMENT RELATES TO:

**IN RE: CLOBETASOL CASES
IN RE: CLOMIPRAMINE CASES**

**16-CB-27242
16-CM-27242**

JOINT STIPULATION REGARDING ANSWER DEADLINES

WHEREAS, on November 9, 2020, certain Defendants filed their *Joint Motion to Dismiss Certain State Law Claims and to Strike Certain Allegations in the Consolidated Amended End-Payer Class Action Complaints* (“Joint Motion”), in the above-captioned cases;¹

WHEREAS, in Pretrial Order No. 171 (May 7, 2021), the Court selected the End-Payer Plaintiffs’ Clobetasol and Clomipramine complaints as bellwether cases and directed the parties to, *inter alia*, submit proposed schedules to bring to trial the EPP complaints as to Clobetasol and Clomipramine;

WHEREAS, after meeting and conferring, the parties have agreed on an appropriate deadline for the filing of Answers in the above-captioned cases in the event the Court denies the Joint Motion in the relevant case(s);

It is hereby STIPULATED AND AGREED, by and among the undersigned counsel as follows:

¹ See *In re Clobetasol Cases*, 16-CB-27242, ECF 186 and *In re Clomipramine Cases*, 16-CM-27242, ECF 142. The Joint Motion was also filed in *In re Pravastatin Cases*, 16-PV-27242, ECF 173, but the EPP complaint as to Pravastatin is outside of the scope of the present stipulation.

1. Defendants shall file Answers in the above-captioned cases within 45 days of any Order denying the Joint Motion;

2. In the event the Court grants any aspect of the Joint Motion, within 14 days the parties shall meet and confer regarding whether a different deadline for Answers or other filings may be appropriate.

It is so **STIPULATED**.

Dated: July 28, 2021

/s/ Roberta D. Liebenberg
Roberta D. Liebenberg
FINE, KAPLAN AND BLACK, R.P.C.
One South Broad St., 23rd Fl.,
Philadelphia, PA 19107
Tel: (215) 567-6565
rliebenberg@finekaplan.com

***Lead and Liaison Counsel for the End-Payer
Plaintiffs***

Respectfully submitted,

/s/ Jan P. Levine
Jan P. Levine
TROUTMAN PEPPER HAMILTON SAMPSON
3000 Two Logan Square
Eighteenth & Arch Streets
Philadelphia, PA 19103-2799
Tel: (215) 981-4000
jan.levine@troutman.com

/s/ Sheron Korpus
Sheron Korpus
KASOWITZ BENSON TORRES LLP
1633 Broadway
New York, NY 10019
Tel: (212) 506-1700
skorpus@kasowitz.com

/s/ Devora W. Allon
Devora W. Allon
KIRKLAND & ELLIS LLP
601 Lexington Avenue
New York, NY 10022
Tel: (212) 446-5967
devora.allon@kirkland.com

/s/ Chul Pak
Chul Pak
WILSON SONSINI GOODRICH & ROS
1301 Avenue of the Americas, 40th Fl.
New York, NY 10019

Tel: (212) 999-5800
cpak@wsgr.com

/s/ Sarah F. Kirkpatrick
Sarah F. Kirkpatrick
WILLIAMS & CONNOLLY, LLC
725 Twelfth Street, N.W.
Washington, D.C. 20005
Tel: (202) 434-5958
skirkpatrick@wc.com

Defendants' Liaison Counsel